Details for Patent: 8,404,724

Which drugs does patent 8,404,724 protect, and when does it expire?

Patent 8,404,724 protects BEVYXXA and is included in one NDA.

This patent has twenty-four patent family members in nineteen countries.

Summary for Patent: 8,404,724

Title:	Unit dose formulations and methods of treating thrombosis with an oral factor Xa inhibitor
Abstract:	Unit doses of factor Xa inhibitor compounds and methods of using these compounds for inhibiting blood coagulation in a human patient are taught herein. The unit dose of the factor Xa inhibitor compounds disclosed herein required to inhibit coagulation in a primate is lower than the unit dose required to obtain similar levels of coagulation inhibition in other animal models, such as rodents. Also taught are in vitro assays useful in predicting in vivo antithrombotic activity in humans.
Inventor(s):	Sinha; Uma (San Francisco, CA), Hollenbach; Stanley J. (South San Francisco, CA), Abe; Keith (South San Francisco, CA)
Assignee:	Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	11/999,957
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 8,404,724

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-001	Jun 23, 2017		DISCN	Yes	No			Y			INHIBITING COAGULATION
Portola Pharms Inc	BEVYXXA	betrixaban	CAPSULE;ORAL	208383-002	Jun 23, 2017		DISCN	Yes	No			Y			INHIBITING COAGULATION

International Family Members for US Patent 8,404,724

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2007333377
Canada	2671502
Canada	2913963